BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Inhibitor Therapeutics, Inc. INTI
14 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-0.02
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-952.3%
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 14-year series below
Revenue
Net income
Per share
USD -0.02
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-952.3%
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-80.4%
Each USD of equity lost 952 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.17B
Shares outstanding, FY2025
Change, 5 years+6.6%
Change, 10 years—
The share count grew 7% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 2.5M
total assets, end of FY2025
Total assetsUSD 2.5M
EquityUSD -1.3M
CashUSD 2.4M
Gross debtUSD 36,889.00
Net debtUSD -2.3M
Current ratio3.19×
The company holds more cash than debt.
History
14 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
Revenue $B
·
·
·
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
·
·
·
·
·
·
·
·
·
·
·
·
−0.0
−0.0
Income tax $B
·
·
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
Net income $B
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
EPS, diluted $
−0.02
−0.02
−0.02
0.03
0.00
0.00
−0.01
−0.01
−0.01
−0.02
−0.02
−0.04
−0.10
0.01
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
−0
−4
·
·
·
·
·
·
·
ROE %
−952.3
−91.9
−44.6
517.9
·
·
·
−4575.1
−141.8
−187.8
−1625.1
·
·
·
Shares out B
0.17
0.17
0.17
0.17
0.38
0.37
0.37
0.37
0.37
0.35
0.25
0.21
0.02
0.02
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
40 of 40
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed